S1 Biopharma
CompanyUnited StatesFounded 2010
S1 Biopharma develops one asset, in phase 1 (Lorexys in hypoactive sexual desire disorder). Mostly small molecule acting on SLC6A2 and SLC6A3; based in the United States, founded in 2010.
- 1
- Asset
- Furthest stage
- Phase 1
- 1
- Trial
- 1
- Signal
Pipeline
1Norepinephrine and dopamine reuptake inhibitor formulation
Phase 1, Small molecule, SLC6A2, SLC6A3, hypoactive sexual desire disorder, sexual interest arousal disorder
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials1
- Signals1
- Similar companies6